Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. [electronic resource]
Producer: 20120906Description: 784-91 p. digitalISSN:- 1592-8721
- Adult
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors -- therapeutic use
- Antineoplastic Agents, Hormonal -- therapeutic use
- Dexamethasone -- therapeutic use
- Disease Progression
- Drug Resistance, Neoplasm
- Female
- Follow-Up Studies
- Humans
- International Agencies
- Male
- Middle Aged
- Multiple Myeloma -- drug therapy
- Neoplasm Recurrence, Local -- drug therapy
- Neoplasm Staging
- Prognosis
- Prospective Studies
- Remission Induction
- Salvage Therapy
- Survival Rate
- Thalidomide -- therapeutic use
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.